Milan, Italy

Marco Ballarini



Average Co-Inventor Count = 7.6

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2010-2014

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Marco Ballarini: Innovator in Mitochondrial Therapeutics

Introduction

Marco Ballarini is a prominent inventor based in Milan, Italy. He has made significant contributions to the field of therapeutic agents, particularly those targeting mitochondrial functions. With a total of five patents to his name, Ballarini's work focuses on innovative solutions for diseases associated with mitochondrial permeability transition.

Latest Patents

Among his latest patents are the "Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition." These derivatives serve as therapeutic agents aimed at preventing and treating conditions linked to the mitochondrial permeability transition pore (MPTP). The patents detail compounds that are effective against diseases characterized by ischemia/reperfusion and oxidative or degenerative tissue damage. The structural formula of these compounds is defined in the specifications, which also cover their preparation and pharmaceutical compositions.

Career Highlights

Throughout his career, Marco Ballarini has worked with notable companies such as Dac S.r.l. and Congenia S.r.l. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Some of his notable coworkers include Saverio Minucci and Antonello Mai. Their collaborative efforts have further advanced the research and development of mitochondrial therapeutics.

Conclusion

Marco Ballarini stands out as a key figure in the field of mitochondrial therapeutics, with a focus on innovative acrylomido derivatives. His contributions through patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…